Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects

HIV Clinical Trials
Carosi Nichols

Abstract

Fosamprenavir/ritonavir 1400 mg/100 mg once-daily regimen may have a more favourable tolerability and lipid profile than the fosamprenavir/ritonavir twice-daily regimen, while maintaining comparable antiviral efficacy. This open-label study had a group-sequential design with a stage 1 Week 24 futility analysis, with both efficacy and safety go-criteria for progression to stage 2. There were 214 antiretroviral-naive, HIV-1-infected subjects who were randomised to receive either fosamprenavir/ritonavir 1400 mg/100 mg once daily or fosamprenavir/ ritonavir 700 mg/100 mg twice daily, both with abacavir/lamivudine fixed-dose combination tablet. Primary endpoints were the proportion of subjects achieving HIV-1 RNA <400 copies/mL at Week 48 and the mean change from baseline in fasting non-HDL cholesterol. Though stage 1 futility analysis did not meet criteria for progression to stage 2, subjects enrolled in stage 1 were followed to Week 48 per protocol. At Week 48, noninferior efficacy of once daily to twice daily (95% CI around the treatment difference, -11.4 to 9.5) was achieved, with 86/106 (81%) subjects in the once-daily and 87/106 (82%) in the twice-daily arm achieving HIV-1 RNA <400 copies/mL. Mean change from baseline at Week ...Continue Reading

References

Aug 8, 1998·The New England Journal of Medicine·S H MichaelsP Kissinger
Aug 28, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael P DubéUNKNOWN HIV Medical Association of the Infectious Disease Society of America
Apr 27, 2007·The New England Journal of Medicine·UNKNOWN DAD Study GroupJens D Lundgren
Apr 3, 2008·Pharmaceutical Statistics·Sara HughesW Garrett Nichols
Jun 17, 2008·The Journal of Infection·S BadiouUNKNOWN Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA)
Jun 18, 2009·Current Opinion in HIV and AIDS·Mark A Boyd

❮ Previous
Next ❯

Citations

Dec 1, 2011·The Journal of Antimicrobial Chemotherapy·José A Pérez-MolinaSantiago Moreno
Jun 22, 2011·AIDS Patient Care and STDs·Nicolás MerchanteUNKNOWN Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
Jul 27, 2011·Expert Opinion on Pharmacotherapy·Giuliano Rizzardini, Patrizia Zucchi
Apr 16, 2013·Revista da Associação Médica Brasileira·Suelen Jorge SouzaPatrícia Helen Carvalho Rondó
Jul 19, 2012·Pharmaceutical Statistics·Sara HughesRobert L Cuffe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.